The shadow of generic challenges has consistently loomed over copyright’s blockbuster drug, PDE5 Inhibitor, triggering questions about the future of related pharmaceutical ventures. While early times saw significant profits, the exclusivity lapse has created the way for cheaper copies, possibly reducing revenue and presenting a genuine hazard for